摘要
目的:观察温肾通阳法结合西药治疗妇女糖尿病神经源性膀胱证属中医肾阳亏虚证患者的临床表现、体征、排尿症状评分、排尿症状生活质量评分、尿动力学参数、糖化血红蛋白、血脂等指标的变化情况,对其临床疗效及安全性进行评价。
方法:通过文献研究,回顾中医学与西医学对糖尿病神经源性膀胱的认识,结合导师经验,探讨糖尿病神经源性膀胱的中医病因病机和治疗方法,提出肾阳亏虚是糖尿病神经源性膀胱的重要病理机制,确定以温肾通阳为其治法,并拟结合西医α肾上腺能受体阻滞剂及乌拉胆碱两种药物联合治疗。采用随机平行对照的研究方法将60例糖尿病神经源性膀胱肾阳亏虚证患者随机分为两组,治疗组(中西医结合治疗组)29例,对照组(对照组)31例。在基础治疗(饮食控制、药物控制血糖血脂)的基础上,治疗组服用桂附地黄丸散剂(每次12g,每日3次)及西药盐酸坦索罗辛口服常释剂型(Tamsulosin Hydrochloride,0.2mg)(每次0.2mg,每日1次)和乌拉胆碱(Urecholine,25mg)(每次25mg,每日3次)。对照组不服用中药,两组均以12周为1疗程,治疗前后完善相关检查。观察患者治疗前后临床症状、体征、排尿症状评分、排尿症状生活质量评分、尿动力学参数、糖化血红蛋白、血脂(甘油三酯、总胆固醇)等指标的变化。全部数据以SPSS15.0统计软件进行统计学分析。
结果:确诊并最后纳入的糖尿病神经源性膀胱肾阳虚证患者60例(治疗组29例,对照组31例),治疗前两组的年龄、病程、临床症状体征、排尿症状评分、排尿症状生活质量评分、尿动力学参数、糖化血红蛋白、血脂(甘油三酯、总胆固醇)等基线数据经统计学处理无显着性差异,有可比性(P<0.05)。研究结果:①疗效比较:对照组总有效率25.80%,其中显效2例(6.45%),有效6例(19.35%),无效23例(74.19%)。治疗组,总有效率89.66%,其中显效14例(48.27%),有效12例(41.37%),无效3例(10.34%)。②中医肾阳虚证候:治疗组患者治疗后症状有明显改善,提示治疗组对中医肾阳虚症状的改善作用明显优于对照组(P<0.05)。③改善下尿路症状,排尿生活质量:治疗组排尿症状指数(AUA-SI),排尿症状生活质量评分的改善程度与治疗前比较有明显改善(P<0.05),同时优于对照组(P<0.05),提示桂附地黄丸具有改善下尿路症状及排尿生活质量的作用。④尿动力学参数影响:治疗组患者治疗后最大尿流速、膀胱灌注初始感觉、残留尿、膀胱排空率均明显改善,与治疗前比较均有显着性差异(P<0.05),但膀胱容积、逼尿肌压力治疗后没有统计学意义(P>0.05)。两组间治疗后比较,治疗组最大尿流速、膀胱灌注初始感觉、残留尿、膀胱排空率均改善较对照组有显着差异(P<0.05),提示桂附地黄丸具有改善尿动力学参数的作用。⑤降糖效果:治疗组治疗后糖化血红蛋白有明显下降(P<0.05),与对照组比较有统计学意义(P<0.05),提示桂附地黄丸具有一定的降糖作用。⑥调节血脂:治疗组治疗后甘油三脂及总胆固醇均较治疗前下降(P<0.05);对照组治疗后甘油三脂及总胆固醇水平治疗前后相比均无明显改变(P>0.05)。两组间治疗后比较,治疗组较对照组的甘油三脂及总胆固醇改善有统计学意义(P<0.05),提示桂附地黄丸具有调节血脂的作用。
结论:该研究表明,温肾通阳法结合西药治疗糖尿病神经源性膀胱肾阳虚证优于单纯西药治疗,具有改善排尿症状、提高排尿生活质量作用。尿动力学测定显示桂附地黄丸能提高糖尿病神经源性膀胱肾阳虚证患者的最大尿流速及膀胱排空率,减少其残留尿,但对于膀胱容积及逼尿肌压力的影响不明显。同时本研究也表明桂附地黄丸能明显改善糖尿病神经源性膀胱肾阳虚证患者血糖、血脂,并且无毒副作用,证实该方药安全有效,临床应用于糖尿病神经源性膀胱具有广泛的前景。但因本研究周期较短,临床数据样本偏小,确切疗效仍需进一步大样本、长周期、多中心观察。
Purpose:To study the efficacy of traditional Chinese medicine of warming the kidney and activating yang method for diabetic neurogenic bladder in female with type 2 diabetes mellitus. The clinical symptoms of insufficiency of kidney-YANG, America urological association lower urinary symptom score index, impact of urinary symptoms against quality of life was evaluate. The urodynamic study data including maximum flow rate, residual urine, and first sensation in filling phase, post-voiding residual urine volume, urinary bladder capacity, maximum detrusor pressure and voiding efficacy was collected. The level of serum glycated hemoglobin Alc, total cholesterol and triglycerol were also determined for the difference between control group(western medicine group) and study group(Chinese medicine and western medicine combine treatment group) was compared.
Methods:A randomized, controlled trial was conducted in 60 patients with type 2 diabetes mellitus associated with insufficiency of kidney-YANG. The patients were randomly classified into two groups. Based on ordinary treatment and diet control, the control group (n=31) was treated by tamsulosin orally (0.2mg daily) and urecholine (75 mg daily, divided in three doses).The control group (n=29) was treated by tamsulosin orally (0.2mg daily) and urecholine (75 mg daily, divided in three doses) and Bawei Di Huang Wan (12 gm daily, divided in three doses). The treatment course was 12 weeks. The symptom of insufficiency of kidney-YANG, lower urinary tract symptoms, impact of quality of life by lower urinary tract symptoms was evaluated with questionnaires. The standard videourodynamic study was performed and parameters were recorded. The serum levels of glycated hemoglobin A1C, total cholesterol, triglycerol were also recorded before and after trial. All the data was managed by the SPSS 15.0 statistics software for statistically significance between groups.
Results:Before trial, age, disease course, clinical symptoms of insufficiency of kidney-YANG, lower urinary tract symptom score, impact of quality of life, parameters of urodynamic study, serum level of glycated hemoglobin, total cholesterol, triglycerol showed no statistical differences(P<0.05). The total effective rate in clinical symptoms of insufficiency of kidney-YANG of study group was 89.66%, while the control group was 25.80%. The study group had an advantage than the control group (P<0.05). In terms of lower urinary tract symptoms (AUA-SI) and quality of life, there was improvement in the study group (P<0.05). The study group had significant advantage on the lower urinary tract symptoms (AUA-SI) and quality of life over control group (P<0.05). The urodynamic parameters including maximum urinary flow rate, post-voiding residual volume, first sensation of cystometry, voiding efficacy improved significantly in study group. But bladder capacity, maximum detrusor pressure have no difference after trial (P>0.05). The study group also gained advantage in improvement of maximum urinary flow rate, post-voiding residual volume, first sensation of cystometry, voiding efficacy in comparison with control group (P<0.05). It showed Bawei Di Huang Wan is effective in treating the diabetic nurogenic bladder. The serum level of glycated hemoglobin A1C, total cholesterol, triglycerol lowered after treatment in study group (P<0.05) but not in control group (P>0.05). We concluded that Bawei Di Huang Wan may have advantage in blood sugar and better hyperlipidemia control in diabetic neurogenic bladder patients.
Conclusion:This randomized control study showed that the method of warming the kidney and activating yang of traditional Chinese medicine combine with alpha blockers and cholinergic agents may have synergic effect in treating diabetic neurogenic bladder patients. However, the case number and period of present study is limited, further large scale, long term, multiple centers clinical trial is necessary to clarify the effectiveness and mechanism of Bawei Di Huang Wan for treating lower urinary tract dysfunction in diabetic patients.
引文
[1]李广德.糖尿病及并发症[M].安徽科学技术出版社,2007:1-2
[2]苗述凯,蔡蕙文.糖尿病并发症防治学[M].中国医药科技出版社,2004:1-3
[3]Tai TY, Yang CL, Chang CJ, et al. Epidemiology of diabetes mellitus in Taiwan, ROC-comparison between urban and rural areas. J Med A Thai 1987;70(supp 2):49-53
[4]吴海艳,王旭.中医药治疗糖尿病周围神经病变的研究进展[J].中医药学刊,2006,24(2):309-310
[5]鞠彦合,廖利民.糖尿病膀胱病变与下尿路症状[J].中国康复理论与实践,2005,11(11):890-891
[6]胡志娟,王振显.绝经后2型糖尿病妇女膀胱残余尿水平及其临床意义[J].中国老年学杂志,2009,29(24):3277-3278
[7]曾娇娥,周家杰,宁尚侠,李娟,王景丽,王建国.尿动力学检查在糖尿病神经源性膀胱中的应用价值[J].华中医学杂志,2006,26(3):164-165
[8]靖立新,关永春,郑文菊.神经源性膀胱的临床x线分析[J].牡丹江医学院学报,2008,29(3):73-74
[9]崔喆,尹鉴淳,张和平,李黎明,强万明.尿动力学检查在糖尿患者者膀胱功能评定中的意义[J].中华泌尿外科杂志,2005,26(4):250-252
[10]吴正和,王敏产.糖尿病神经源性膀胱的发病机制及诊治[J].中国误诊学杂志,2004,4(10):1700-1701
[11]曾秀华,黄光玉,贺吉林.糖尿病神经源性膀胧患者排尿功能训练效果观察[J].护理学杂志,1998,13(5):265-266
[12]牛永义中西医结合治疗糖尿病神经源性膀胱的临床观察《中国误诊学杂志》2008,3(8):102-104
[13]吕仁和赵进喜糖尿病及其并发症中西医诊治学(第2版)[M].人民卫生出版社2009: 655-658
[14]中华中医药学会糖尿病中医防治指南[M]中国中医药出版社出版ZYYXH/T3 1-315-2007
[15]曾家丽,郑平,徐波,曾丽琴,陈霞等.行气温阳散烫熨治疗糖尿病神经源性膀胱的效果观察.护理学杂志2009,24(9):49
[16]丘伟中.疏血通注射液联合壮腰健肾丸治疗老年性2型糖尿病性膀胱的临床观察.中西医结合心脑血管病杂志2009年10月第7卷第10期·1231
[17]孙金瑞.益肾灵散治疗糖尿病神经源性膀胱163例.中国民间疗法2009,17(9):26-31
[18]杨震,李蜜蜂.宣肺温肾汤治疗糖尿病神经源性膀胱引发尿潴留30例吉林中医药2006,26(11):20
[19]邬金玲,郭永红,周静,等.针灸治疗糖尿病神经源性膀胱38例[J].中国中医药信息杂志,2004,9(11):819-820
[20]丛科,教富娥.针刺治疗糖尿病神经源性膀胱40例[J].中国实用乡村医生杂志,2007,2(14):35
[21]王清泉,牛莉.针刺治疗糖尿病神经源性膀胱30例[J].中国临床康复,2004,8(21):4254
[22]卢洁荷,王秀清,乔平,等.穴位温灸并低频脉冲电治疗糖尿病神经源性膀胱的疗效观察[J].中国实用护理杂志,2007,3(23):18-19
[23]泌尿外科疾病诊断和鉴别诊断.人民卫生出版社.1988第1版:176
[24]阿部博子.地黄、八味地黄丸的药理及药效[J].国外医药·植物药分册,1992,7(2):61-62
[25]王姝琛,崔为.陈修园《家藏心典》八味地黄丸运用举隅[J].世界中西医结合杂志,2007,2(5):266-267
[26]张家玮.金匮肾气丸临床应用研究概况[桂附地黄丸京中医,2001,3:56-59
[27]高学敏.中药学[M].北京:中国中医药出版社,2002:540
[28]王军,王震,李更生,等.地黄苷A对“阴虚”及免疫功能低下的小鼠的药理作用[J].中国药学杂志,2002,37(1):20~22.
[29]刘福君,赵修南,汤建芳,等.地黄寡糖对SAMP8小鼠造血祖细胞增殖作用[J].中国药理学与毒理学杂志,1998,12(2):127~128.
[30]苗明山,孙艳红,方晓艳.(怀)熟地黄多糖抗氧化作用[J].中国中医药信息杂志,2002,9(10):32~33.
[31]高学敏.中药学[M].北京:中国中医药出版社,2002:578
[32]戴岳,杭秉茜,黄朝林,等.山茱萸对炎症反应的抑制作用[J].中国中药杂志,1992,17(5):307.
[33]李建民,周勇,项静辰,等.山茱萸总甙对正常小鼠T淋巴细胞免疫功能影响的实验研究[J].北京中医药大学学报,2000,23(6):30.
[34]李建民,周勇,张丽,等.山茱萸总甙对HUVEC表达ICAM-1、CD44的影响[J].中国免疫学杂志,2000,16:604.
[35]赵武述.山茱萸的免疫药理研究Ⅱ:总苷部分抑制免疫反应的体外效应[J].中日友好医院学报,1991,5(2):71.
[36]高学敏.中药学[M].北京:中国中医药出版社,2002:505
[37]Maurice M. The Hypoglycemic Principle of Dioscorea dumetorum [J]. Planta Medica,1990,56(1):119
[38]李树英.山药健脾胃作用的研究[J].中药药理与临床,1990,9(4):232.
[39]高学敏.中药学[M].北京:中国中医药出版社,2002:383-384
[40]高学敏.中药学[M].北京:中国中医药出版社,2002:134—139.
[41]高学敏.中药学[M].北京:中国中医药出版社,2002:20.
[42]高学敏.中药学[M].北京:中国中医药出版社,2002:53-54
[43]高学敏.中药学[M].北京:中国中医药出版社,2002:273-274
[44]彭波,杨华元.乌头、附子及其主要生物碱研究进展[J].华西药学杂志,1993,8(3):158-161.
[45]陈信义,李峨,侯丽,等.乌头类生物碱研究进展与应用前景评述[J].中国中医药信息杂志,2004,11(10):922-923.
[46]高学敏.中药学[M].北京:中国中医药出版社,2002:244-245
[47]金琦,曹静,王淑华.大剂量茯苓的药理作用及临床应用概况[J].浙江中医杂志,2003,38(9):410-411.
[48]高学敏.中药学[M].北京:中国中医药出版社,2002:169
[49]高学敏.中药学[M].北京:中国中医药出版社,2002:248
[50]钱文彬,庞红,薛大权.泽泻水提物、醇提物的制备及对小白鼠降脂作用的研究[J].数理医药学杂志,2007,20(6):836-838.
[51]张力华,李开军,薛存宽.泽泻提取物对高同型半胱氨酸血症兔氧化及抗氧化因子的影响[J].中医中药与微循环,2007,17(3):31-3.
[52]王东方,干祖望,余江毅,等.金匮肾气丸拮抗庆大霉素耳毒性作用的机理研究[J]桂附地黄丸药大学学报,1997,13(5):284-286
[53]程嘉艺,孙文静,张予阳.肾气丸方易化阳虚小鼠及老龄大鼠学习记忆能力的实验研究[J].中成药,1992,14(10):33-34
[54]刘叙仪,庞玉滨,赵玉亮,等.六味地黄丸或金匮肾气丸辅助治疗小细胞肺癌的疗效观察——附六味地黄汤及金匮肾气汤对小鼠免疫功能的影响[J].中西医结合杂志,1990,10(12):720-722
[55]周超凡,张静楷.中药复方药理学研究探讨[J].中成药研究,1980,2(3):4-7
[56]狄俊英,崔洪英,苗戎,等.肾气丸与六神丸对靶组织cAMP含量影响的实验研究[J].天津中医,1998,15(4):180-181
[57]陈庆平,郭凌燕.金匮肾气丸、六味地黄丸对小鼠性激素影响的实验研究[J].中国药房,1999,10(6):255
[58]张建新,李兰芳,吴树勋,等.八味地黄口服液药理作用研究[J].中成药,1994,16(3):23-33
[59]岛津孝.用小动物检定糖尿病治疗药的方法及八昧地黄丸的效果[J].国外医学·中医中药分册,1984,6(1):56-57
[60]余美娟,姚晓渝,周思萍,等.金匮。肾气丸对鹌鹑食饵性高脂血症和血清过氧化脂质的影响[J]中国药学杂志,1990,25(7):419-420
[61]小曾户洋.八味地黄丸对加龄的影桂附地黄丸黄丸与谷胱甘肽代谢[J].国外医学·中医中药分册,1984,6(1):57-58
[62]蒋珠芬,田军,杨士友,等.桂附地黄口服液的药理作用[J].中成药,1991,13(11):46
[63]刘宏阳,程士德.按照肾气发育周期因时抗衰的桂附地黄丸八味地黄汤对不桂附地黄丸鼠耐寒、抗疲劳作用及组织MAO、LPO水平影响的观察[J].北京中医学院学报,1987,10(6):33-35
[64]王明艳,吴海涛,赵鸣芳,等.4种方药对环磷酰胺诱发的SCE的抑制作用[J].中成药,2000,22(3):212-214
[65]郑小伟,刘明哲,程志清,等.金匮肾气丸对SD大鼠慢性电离辐射损伤的防护作用[J].中国中医药科技,1999,6(6):382
[66]倪青.糖尿病早期并发症的中西医结合防治思路与方法(一)[J].环球中医药,2008,1(5):10-13
[67]王文章,何家扬,张燕宾,刘芳,陈影.糖尿病性膀胱功能损害的尿动力学分析[J].临床泌尿外科杂志,2007,22(1):33-35
[68]马文义,王海新,孟祥成,史本康,徐祗顺.BPH伴糖尿患者者尿动力学检测的临床意义[J].临床泌尿外科杂志,2007,22(6):454-455
[69]郭汉崇.神经性因排尿障碍[J].台湾医学,2005,9(4):482-488
[70]双卫兵,王东文.糖尿病神经源性膀胱尿道功能障碍的病因学研究[J].山西医科大学学报,2004,35(4):421-423
[71]张勇.辨证治疗糖尿病神经源性膀胱的体会[J].中国现代医药杂志,2007,9(4):135-136
[72]王新民,李路.糖尿病神经源性膀胱的研究进展[J].国外医学内分泌学分册,2001,21(6):328-329
[73]蔡川海,李劲松.中西医结合治疗糖尿病神经源性膀胱30例[J].福建中医学院学报,2006,16(4):26-27
[74]李社莉,成涌.中西医结合治疗糖尿病神经源性膀胱36例[J].中医杂志,1999,40(2):93-94
[75]牛永义.中西医结合治疗糖尿病神经源性膀胱的临床观察[J].中国误诊学杂志,2008,8(8):1817-1818
[76]谭显芳,武庆媛.中西医结合治疗糖尿病膀胱病变42例临床观察[J].中医药导报,2007,13(3):19-20
[77]随子云,栾英辉,任书梅.济生肾气汤加前列地尔治疗糖尿病神经源性膀胱26例临床观察[J].河北中医2009,31(2):241-242
[78]李翠萍,李晓峰,张莹莹.中西医结合治疗糖尿病膀胱15例[J].中国现代医生,2008,46(7):90-93
[79]廖安成.中西医结合治疗糖尿病神经源性膀胱尿潴留疗效观察[J].中国当代医药,2009,16(20):139-140
[80]樊国华.中西医结合治疗糖尿病神经源性膀胱30例疗效观察[J].中国医自强报,2008,5(23):80
[81]刘娟,习杰英,高翠霞.酚妥拉明治疗糖尿病神经源性膀胱疗效观察[J].西医学杂志,2002,31(7):642-643
[82]Shang-Jen Chang,1I-Ni Chiang2 and Hong-Jeng Yu The effectiveness of tamsulosin in treating women with voiding difficulty(J) International Journal of Urology Volume 15 Issue 11, Pages 981-985
[83]马国海.中医药治疗糖尿病神经源性膀胱进展[J].光明中医,2008,23(2):245-246